Expert Ratings for Cytokinetics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 9 analysts have published their opinion on Cytokinetics (NASDAQ:CYTK) stock, with an average price target of $60.56, implying an upside from the current price of $35.5. The current average has increased by 12.15% from the previous average price target of $54.00. The majority of the ratings are bullish.
November 09, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have a bullish outlook on Cytokinetics, with an average price target of $60.56, implying an upside from the current price of $35.5.
The bullish outlook from analysts indicates a positive sentiment towards Cytokinetics. The average price target of $60.56, which is significantly higher than the current price, suggests that analysts expect the stock to perform well in the future. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100